These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 11378653)
1. Hyperthermic isolated limb perfusion for extremity sarcomas. Kim CJ; Puleo C; Letson GD; Reintgen D Cancer Control; 2001; 8(3):269-73. PubMed ID: 11378653 [TBL] [Abstract][Full Text] [Related]
2. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile? Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110 [TBL] [Abstract][Full Text] [Related]
3. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas]. Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611 [TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Bickels J; Manusama ER; Gutman M; Eggermont AM; Kollender Y; Abu-Abid S; Van Geel AN; Lev-Shlush D; Klausner JM; Meller I Eur J Surg Oncol; 1999 Oct; 25(5):509-14. PubMed ID: 10527599 [TBL] [Abstract][Full Text] [Related]
5. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Komdeur R; Plaat BE; Hoekstra HJ; Molenaar WM; Hollema H; van den Berg E; Mastik MF; van der Graaf WT Cancer; 2001 May; 91(10):1940-8. PubMed ID: 11346877 [TBL] [Abstract][Full Text] [Related]
6. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment. Grabellus F; Sheu SY; Tötsch M; Lehmann N; Kaiser GM; Jasani B; Taeger G; Schmid KW J Surg Oncol; 2010 May; 101(6):465-70. PubMed ID: 20401916 [TBL] [Abstract][Full Text] [Related]
8. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study. Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294 [TBL] [Abstract][Full Text] [Related]
9. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039 [TBL] [Abstract][Full Text] [Related]